

DAFTAR PUSTAKA

- ADA. (2020). *Standards of Medical Care in Diabetes — 2020 Abridged for Primary Care Providers*. 29.
- Agung, P. (2017). *Metode Penelitian Kuantitatif dan Kualitatif* (A. Yuesti, Ed.). Universitas Mahasaraswati Denpasar.
- Ain, Q., Latif, A., Jaffar, S. R., & Ijaz, A. (2017). Evaluation of random plasma glucose for assessment of glycaemic control in type 2 diabetes mellitus. *Journal of the Pakistan Medical Association*, 67(9), 1353–1356.
- Akmal, M., & Wadhwa, R. (2022). *Alpha Glucosidase Inhibitors*. <https://www.ncbi.nlm.nih.gov/books/NBK557848/>
- Alssema, M., Ruijgrok, C., Blaak, E. E., Egli, L., Dussort, P., Vinoy, S., Dekker, J. M., & Denise Robertson, M. (2021). Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis. *Nutrition & Diabetes* 2021 11:1, 11(1), 1–9. <https://doi.org/10.1038/s41387-021-00152-5>
- Alzarea, A. I., Khan, Y. H., Alanazi, A. S., Butt, M. H., Almalki, Z. S., AlAhmari, A. K., Alsaahli, S., & Mallhi, T. H. (2022). Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries. *International Journal of Environmental Research and Public Health*, 19(13), 7862. <https://doi.org/10.3390/IJERPH19137862>
- Arnold, R. J. (2021). *Pharmacoeconomics : From theory to practice* (Second Edi, Issue December). CRC Press.
- Babar, Z. U. D. (2016). Economic Evaluation of Pharmacy Services. In *Economic Evaluation of Pharmacy Services*. <https://doi.org/10.1016/j.sapharm.2017.02.012>
- Babiker, A., & Dubayee, M. al. (2017). Anti-diabetic medications: How to make a choice? *Sudanese Journal of Paediatrics*, 17(2), 11. <https://doi.org/10.24911/SJP.2017.2.12>
- Bahendeka, S., Wesonga, R., Mutungi, G., Muwonge, J., Neema, S., & Guwatudde, D. (2016). Prevalence and correlates of diabetes mellitus in Uganda: a population-based national survey. *Tropical Medicine & International Health : TM & IH*, 21(3), 405–416. <https://doi.org/10.1111/TMI.12663>

- Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. *Avicenna Journal of Medicine*, *10*(4), 174. https://doi.org/10.4103/AJM.AJM_53_20
- Blonde, L., Dipp, S., & Cadena, D. (2018). Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. *Advances in Therapy*, *35*(7), 939–965. <https://doi.org/10.1007/S12325-018-0694-0/FIGURES/2>
- Bommer, C., Sagalova, V., Heesemann, E., Manne-Goehler, J., Atun, R., Bärnighausen, T., Davies, J., & Vollmer, S. (2018). Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. *Diabetes Care*, *41*(5), 963–970. <https://doi.org/10.2337/DC17-1962>
- BPJS Kesehatan*. (n.d.). Retrieved June 19, 2022, from <https://www.bpjs-kesehatan.go.id/bpjs/>
- Burcelin, R., & Gourdy, P. (2017). Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. *Obesity Reviews: An Official Journal of the International Association for the Study of Obesity*, *18*(1), 86–98. <https://doi.org/10.1111/OBR.12465>
- Carrillo-Larco, R. M., Barengo, N. C., Albitres-Flores, L., & Bernabe-Ortiz, A. (2019). The risk of mortality among people with type 2 diabetes in Latin America: A systematic review and meta-analysis of population-based cohort studies. *Diabetes/Metabolism Research and Reviews*, *35*(4). <https://doi.org/10.1002/DMRR.3139>
- CDC. (2021). *CDC*. <https://www.cdc.gov/policy/polaris/economics/cost-effectiveness/index.html>
- Chan, C. W., Yu, C. L., Lin, J. C., Hsieh, Y. C., Lin, C. C., Hung, C. Y., Li, C. H., Liao, Y. C., Lo, C. P., Huang, J. L., Lin, C. H., & Wu, T. J. (2018). Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: A nationwide cohort observational study. *Cardiovascular Diabetology*, *17*(1), 1–13. <https://doi.org/10.1186/S12933-018-0663-6/TABLES/3>
- Chaudhury, A., Duvoor, C., Dendi, V. S. R., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. *Frontiers in Endocrinology*, *8*. <https://doi.org/10.3389/FENDO.2017.00006>

- Chia, C. W., Egan, J. M., & Ferrucci, L. (2018). Age-related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. *Circulation Research*, *123*(7), 886. <https://doi.org/10.1161/CIRCRESAHA.118.312806>
- Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Research and Clinical Practice*, *138*, 271–281. <https://doi.org/10.1016/J.DIABRES.2018.02.023>
- Dahlan, S. (2013). *Sample Size & Sampling Method in Medicine and Health Research (Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan)*.
- Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *41*(12), 2669–2701. <https://doi.org/10.2337/DC18-0033>
- Deacon, C. F. (2019). Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. *Frontiers in Endocrinology*, *10*, 80. <https://doi.org/10.3389/FENDO.2019.00080>
- Dessie, G., Mulugeta, H., Amare, D., Negesse, A., Wagnew, F., Getaneh, T., Endalamew, A., Adamu, Y. W., Tadesse, G., Workineh, A., & Lebu, S. (2020). A systematic analysis on prevalence and sub-regional distribution of undiagnosed diabetes mellitus among adults in African countries. *Journal of Diabetes and Metabolic Disorders*, *19*(2), 1931. <https://doi.org/10.1007/S40200-020-00635-9>
- Devarajan, T., Venkataraman, S., Kandasamy, N., Oomman, A., Boorugu, H., Karupiah, S. K. P., & Balat, D. (2017). Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. *Indian Journal of Endocrinology and Metabolism*, *21*(5), 745. https://doi.org/10.4103/IJEM.IJEM_176_17
- Dinkes Sumedang. (2021). *Profil Dinas Kesehatan Kabupaten Sumedang*.
- Donner, T., & Sarkar, S. (2019). Insulin – Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy. *Endotext*. <https://www.ncbi.nlm.nih.gov/books/NBK278938/>

- Douros, A., Dell’Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2018). Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. *BMJ*, *362*, 2693. <https://doi.org/10.1136/BMJ.K2693>
- Drzewoski, J., & Hanefeld, M. (2021). The current and potential therapeutic use of metformin—the good old drug. *Pharmaceuticals*, *14*(2), 1–33. <https://doi.org/10.3390/ph14020122>
- Eggleton, J. S., & Jialal, I. (2022). Thiazolidinediones. *XPharm: The Comprehensive Pharmacology Reference*, 1–2. <https://doi.org/10.1016/B978-008055232-3.61047-5>
- Fang, H. S. A., Gao, Q., Tan, W. Y., Lee, M. L., Hsu, W., & Tan, N. C. (2022). The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study. *BMC Medicine*, *20*(1), 1–12. <https://doi.org/10.1186/S12916-021-02221-Z/FIGURES/3>
- Farhadnejad, H., Teymoori, F., Asghari, G., Mokhtari, E., Mirmiran, P., & Azizi, F. (2022). The higher adherence to a healthy lifestyle score is associated with a decreased risk of type 2 diabetes in Iranian adults. *BMC Endocrine Disorders*, *22*(1). <https://doi.org/10.1186/S12902-022-00961-4>
- Fazeli, P. K., Lee, H., Steinhauser, M. L., Women’s Hospital, B., & Pasteur, A. L. (2020). Clinical Section / Letter to the Editor Aging Is a Powerful Risk Factor for Type 2 Diabetes Mellitus Independent of Body Mass Index. *Gerontology*, *66*, 20. <https://doi.org/10.1159/000501745>
- Fitriyani, F., Andrajati, R., & Trisna, Y. (2021). Analisis Efektivitas-Biaya Terapi Kombinasi Metformin-Insulin dan Metformin-Sulfonilurea pada Pasien Rawat Jalan dengan Diabetes Melitus Tipe 2 di RSUPN Dr. Cipto Mangunkusumo. *Indonesian Journal of Clinical Pharmacy*, *10*(1), 10. <https://doi.org/10.15416/ijcp.2021.10.1.10>
- Franz, M. J., Boucher, J. L., Rutten-Ramos, S., & VanWormer, J. J. (2015). Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. *Journal of the Academy of Nutrition and Dietetics*, *115*(9), 1447–1463. <https://doi.org/10.1016/J.JAND.2015.02.031>
- Galaviz, K. I., Narayan, K. M. V., Lobelo, F., & Weber, M. B. (2018). Lifestyle and the Prevention of Type 2 Diabetes: A Status Report. *American Journal of Lifestyle Medicine*, *12*(1), 4. <https://doi.org/10.1177/1559827615619159>

- Ganesan, K., Rana, M. B. M., & Sultan, S. (2022). Oral Hypoglycemic Medications. *StatPearls*.
<https://www.ncbi.nlm.nih.gov/books/NBK482386/>
- Goyal, R. (2021). *Diabetes Mellitus Type 2 - StatPearls - NCBI Bookshelf*.
<https://www.ncbi.nlm.nih.gov/books/NBK513253/>
- Gu, S., Shi, J., Tang, Z., Sawhney, M., Hu, H., Shi, L., Fonseca, V., & Dong, H. (2015). Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. *PLoS ONE*, *10*(5). <https://doi.org/10.1371/JOURNAL.PONE.0126704>
- Gu, S., Tang, Z., Shi, L., Sawhney, M., Hu, H., & Dong, H. (2015). Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. *Value in Health Regional Issues*, *6*, 84–88. <https://doi.org/10.1016/J.VHRI.2015.03.012>
- Guidelines*. (n.d.). Retrieved June 29, 2022, from <https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html>
- Gupta, N., Verma, R., Dhiman, R. K., Rajsekhar, K., & Prinja, S. (2020). Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians. *Journal of Clinical and Experimental Hepatology*, *10*(2), 177–184. <https://doi.org/10.1016/J.JCEH.2019.11.001>
- Haq, F. U., Siraj, A., Ameer, M. A., Hamid, T., Rahman, M., Khan, S., & Masud, S. (2021). Comparative Review of Drugs Used in Diabetes Mellitus-New and Old. *Journal of Diabetes Mellitus*, *11*, 115–131. <https://doi.org/10.4236/jdm.2021.114009>
- Harreiter, J., & Kautzky-Willer, A. (2018). Sex and Gender Differences in Prevention of Type 2 Diabetes. *Frontiers in Endocrinology*, *9*(MAY). <https://doi.org/10.3389/FENDO.2018.00220>
- Hossain, U., Das, A. K., Ghosh, S., & Sil, P. C. (2020). An overview on the role of bioactive α -glucosidase inhibitors in ameliorating diabetic complications. *Food and Chemical Toxicology*, *145*, 111738. <https://doi.org/10.1016/J.FCT.2020.111738>
- International Diabetes Federation - Home*. (n.d.). Retrieved June 19, 2022, from <https://www.idf.org/>
- Ismail, L., Materwala, H., & al Kaabi, J. (2021). Association of risk factors with type 2 diabetes: A systematic review. *Computational and Structural Biotechnology Journal*, *19*, 1759–1785. <https://doi.org/10.1016/J.CSBJ.2021.03.003>

- Isnani, N., Mulyani, M., Zaini, M., & Arif Riyadi, M. (2021). ANALISIS EFEKTIVITAS BIAYA (COST-EFFECTIVENESS) PENGGUNAAN ANTIDIABETES ORAL KOMBINASI PADA PASIEN DIABETES MELITUS TIPE II RAWAT JALAN DI RSUD Dr. H. MOCH. ANSARI SALEH BANJARMASIN. *Jurnal Insan Farmasi Indonesia*, 4(1), 103–110. <https://doi.org/10.36387/jifi.v4i1.683>
- Jagannathan, R., Neves, J. S., Dorcely, B., Chung, S. T., Tamura, K., Rhee, M., & Bergman, M. (2020). The Oral Glucose Tolerance Test: 100 Years Later. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 13, 3787. <https://doi.org/10.2147/DMSO.S246062>
- Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., Chen, L., Dou, J., Guo, X., Kuang, H., Li, L., Li, Q., Li, X., Liu, J., Ran, X., ... Zhao, Z. (2019). Standards of medical care for type 2 diabetes in China 2019. *Diabetes/Metabolism Research and Reviews*, 35(6), e3158. <https://doi.org/10.1002/DMRR.3158>
- Joung, K. I., Jung, G. W., Park, H. H., Lee, H., Park, S. H., & Shin, J. Y. (2020). Gender differences in adverse event reports associated with antidiabetic drugs. *Scientific Reports 2020 10:1*, 10(1), 1–10. <https://doi.org/10.1038/s41598-020-74000-4>
- Jude, E. B., O’leary, C., Myland, M., Nixon, | Mark, Gooch, | Nick, Shaunik, A., & Lew, E. (2020). Evaluating glycaemic control in patients poorly controlled on oral antidiabetic drugs in real-world setting: Results from assessing the Appropriate Timing of Type 2 diabetes INTensification (ATTAIN). *Endocrinology, Diabetes & Metabolism*, 3(1), e00094. <https://doi.org/10.1002/EDM2.94>
- Juni, M. H., Rosliza, A. M., & Faisal, I. (2017). Designing and conducting cost-effectiveness analysis studies in healthcare. *International Journal of Public Health and Clinical Sciences*, 4(5), 62–76. https://www.researchgate.net/publication/323412922_Designing_and_Conducting_Cost-Effectiveness_Analysis_Studies_in_Healthcare%0Ahttps://www.researchgate.net/publication/323412922_Designing_and_Conducting_Cost-Effectiveness_Analysis_Studies_in_Healthcare/c
- Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Shammari, S. al, Shrestha, D., Shaikh, K., Abhayaratna, S., Shrestha, P. K., Mahalingam, A., Askheta, M., Rahim, A. A. A., Eliana, F., Shrestha, H. K., Chaudhary, S., Ngugi, N., ... Das, A. K. (2018). Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus - International Task Force. *Indian Journal of Endocrinology and Metabolism*, 22(1), 132–157. https://doi.org/10.4103/ijem.IJEM_556_17

- Kalra, S., Das, A. K., Baruah, M. P., Unnikrishnan, A. G., Dasgupta, A., Shah, P., Sahay, R., Shukla, R., Das, S., Tiwaskar, M., Vijayakumar, G., Chawla, M., Eliana, F., Suastika, K., Orabi, A., Rahim, A. A. A., Uloko, A., Bahendeka, S., Abdela, A. A., ... Czupryniak, L. (2019). Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group. *Diabetes Therapy* 2019 10:5, 10(5), 1577–1593. <https://doi.org/10.1007/S13300-019-0651-1>
- Kasina, S. V. S. K., & Baradhi, K. M. (2022). *Dipeptidyl Peptidase IV (DPP IV) Inhibitors. Dpp Iv*, 1–5. <https://www.ncbi.nlm.nih.gov/books/NBK542331/>
- Kato, S., Ando, M., Honda, H., Yoshida, Y., Imaizumi, T., Yamamoto, N., & Maruyama, S. (2020). Effectiveness of Lifestyle Intervention Using the Internet of Things System for Individuals with Early Type 2 Diabetes Mellitus. *Internal Medicine*, 59(1), 45. <https://doi.org/10.2169/INTERNALMEDICINE.3150-19>
- Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocrine Reviews*, 37(3), 278–316. <https://doi.org/10.1210/ER.2015-1137>
- Kementerian Kesehatan RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi* (P. Sarnianto, Ed.). <http://farmalkes.kemkes.go.id/unduh/pedoman-penerapan-kajian-farmakoekonomi/>
- Kementerian Kesehatan RI. (2018). Riskesdas. In *Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan*. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB). <https://ejournal2.litbang.kemkes.go.id/index.php/lpb/article/view/3662>
- Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Kaabi, J. al. (2020). Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. *Journal of Epidemiology and Global Health*, 10(1), 107. <https://doi.org/10.2991/JEGH.K.191028.001>
- Kim, D. D., Silver, M. C., Kunst, N., Cohen, J. T., Ollendorf, D. A., & Neumann, P. J. (2020). Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. *Pharmacoeconomics*, 38(10), 1135. <https://doi.org/10.1007/S40273-020-00942-2>
- Kim, H.-Y. (2019). Statistical notes for clinical researchers: the independent samples t-test. *Restorative Dentistry & Endodontics*, 44(3). <https://doi.org/10.5395/RDE.2019.44.E26>

- Lachman, P., Brennan, J., Fitzsimons, J., Jayadev, A., & Runnacles, J. (2022). The economics of patient safety. *Oxford Professional Practice: Handbook of Patient Safety, March*, 43–54. <https://doi.org/10.1093/med/9780192846877.003.0005>
- Lee, B. W., Kim, J. H., Ko, S. H., Hur, K. Y., Kim, N. H., Rhee, S. Y., Kim, H. J., Moon, M. K., Park, S. O., Choi, K. M., Kim, T. N., Lee, Y. H., Kim, J. H., Hong, E. G., Kim, J., Lee, W. Y., Song, B., Kim, J. Y., Yang, D. H., ... Hyeongjin Kim. (2017). Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017. *Diabetes & Metabolism Journal*, 41(5), 367. <https://doi.org/10.4093/DMJ.2017.41.5.367>
- Lee, P. G., & Halter, J. B. (2017). The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations. *Diabetes Care*, 40(4), 444–452. <https://doi.org/10.2337/DC16-1732>
- Li, J., Ni, J., Wu, Y., Zhang, H., Liu, J., Tu, J., Cui, J., Ning, X., & Wang, J. (2019). Sex differences in the prevalence, awareness, treatment, and control of diabetes mellitus among adults aged 45 years and older in rural areas of northern China: A cross-sectional, population-based study. *Frontiers in Endocrinology*, 10(MAR), 147. <https://doi.org/10.3389/FENDO.2019.00147/BIBTEX>
- Lin, L. K., Sun, Y., Heng, B. H., Kwang Chew, D. E., & Chong, P. N. (2017). Medication adherence and glycemic control among newly diagnosed diabetes patients. *BMJ Open Diabetes Research & Care*, 5(1). <https://doi.org/10.1136/BMJDR-2017-000429>
- Liu, X., Zeng, L., & Xu, W. (2018). Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes. *Pakistan Journal of Pharmaceutical Sciences*, 31(3), 1103–1107.
- LKPP. (2022). *LKPP - Lembaga Kebijakan Pengadaan Barang Jasa Pemerintah*. <http://www.lkpp.go.id/v3/>
- Machado-Alba, J. E., Medina-Morales, D. A., & Echeverri-Cataño, L. F. (2016). Evaluation of the quality of life of patients with diabetes mellitus treated with conventional or analogue insulins. *Diabetes Research and Clinical Practice*, 116, 237–243. <https://doi.org/10.1016/j.diabres.2016.04.039>
- Magge, S. N., Silverstein, J., Elder, D., Nadeau, K., & Hannon, T. S. (2020). Evaluation and Treatment of Prediabetes in Youth. *The Journal of Pediatrics*, 219, 11. <https://doi.org/10.1016/J.JPEDI.2019.12.061>

- Masuch, A., Friedrich, N., Roth, J., Nauck, M., Müller, U. A., & Petersmann, A. (2019). Preventing misdiagnosis of diabetes in the elderly: Age-dependent HbA1c reference intervals derived from two population-based study cohorts. *BMC Endocrine Disorders*, *19*(1), 1–10. <https://doi.org/10.1186/S12902-019-0338-7/TABLES/3>
- Matthews, D., del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldanius, P. M. (2020). Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. *Diabetes Therapy*, *11*(11), 2465–2476. <https://doi.org/10.1007/S13300-020-00926-7/FIGURES/5>
- Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., Pihoker, C., Saydah, S., & Wagenknecht, L. (2017). Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *New England Journal of Medicine*, *376*(15), 1419–1429. https://doi.org/10.1056/NEJMOA1610187/SUPPL_FILE/NEJMOA1610187_DISCLOSURES.PDF
- McIver, L. A., & Tripp, J. (2022). Acarbose. *XPharm: The Comprehensive Pharmacology Reference*, 1–3. <https://doi.org/10.1016/B978-008055232-3.61152-3>
- Mishra, P., Pandey, C. M., Singh, U., Gupta, A., Sahu, C., & Keshri, A. (2019). Descriptive Statistics and Normality Tests for Statistical Data. *Annals of Cardiac Anaesthesia*, *22*(1), 67. https://doi.org/10.4103/ACA.ACA_157_18
- Mishra, P., Singh, U., Pandey, C. M., Mishra, P., & Pandey, G. (2019). Application of Student's t-test, Analysis of Variance, and Covariance. *Annals of Cardiac Anaesthesia*, *22*(4), 407. https://doi.org/10.4103/ACA.ACA_94_19
- Mohan, V., Saboo, B., Khader, J., Modi, K. D., Jindal, S., Wangnoo, S. K., & Amarnath, S. (2022). Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines: <https://doi.org/10.1177/11795514221074663>, 15. <https://doi.org/10.1177/11795514221074663>
- Morrow, J., & Laher, A. (2022). Financial burden associated with attendance at a public hospital emergency department in Johannesburg. *African Journal of Emergency Medicine*, *12*(2), 102. <https://doi.org/10.1016/J.AFJEM.2022.02.002>

- Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 32(1), 193–203. <https://doi.org/10.2337/DC08-9025>
- Nishiyama, K., Toshimoto, K., Lee, W., Ishiguro, N., Bister, B., & Sugiyama, Y. (2019). Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine. *CPT: Pharmacometrics & Systems Pharmacology*, 8(6), 396–406. <https://doi.org/10.1002/PSP4.12398>
- Nuryadi. (2017). *Dasar-dasar Statistik Penelitian (kesatu)*. Sibuku Media. www.sibuku.com
- Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018). Association between insulin resistance and the development of cardiovascular disease. *Cardiovascular Diabetology* 2018 17:1, 17(1), 1–14. <https://doi.org/10.1186/S12933-018-0762-4>
- Ortiz-Martínez, M., González-González, M., Martagón, A. J., Hlavinka, V., Willson, R. C., & Rito-Palomares, M. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. *Current Diabetes Reports*, 22(3), 95–115. <https://doi.org/10.1007/S11892-022-01453-4/TABLES/4>
- Pantaleon, L. (2019). Why measuring outcomes is important in health care. *Journal of Veterinary Internal Medicine*, 33(2), 356. <https://doi.org/10.1111/JVIM.15458>
- Patoulas, D., Papadopoulos, C., Stavropoulos, K., Zografou, I., Doumas, M., & Karagiannis, A. (2020). Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. *Journal of Clinical Hypertension (Greenwich, Conn.)*, 22(4), 562–571. <https://doi.org/10.1111/JCH.13831>
- Perkeni. (2021). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia*. PB. Perkeni. <https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-Website-Pedoman-Pengelolaan-dan-Pencegahan-DMT2-Ebook.pdf>
- Pribadi, F. (2018). *Analysis of the Cost-Effectiveness of Antidiabetic Drugs among Self Paid Participant of the Indonesia National Security Service (NSS) with Type 2 Diabetes Mellitus*.

- Priyono. (2016). *Metode Penelitian Kuantitatif* (T. Chandra, Ed.; Edisi Revi). Zifatama Publishing.
- Putra, S. (2021). *ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN TERAPI INSULIN DAN INSULIN KOMBINASI PADA PASIEN DIABETES MELLITUS TIPE II ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN TERAPI INSULIN DAN INSULIN KOMBINASI PADA PASIEN DIABETES MELLITUS TIPE II RAWAT JALAN DI RSUP SANGLAH A.*
- Qaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., Fitterman, N., Boyd, C., Horwitch, C., Iorio, A., Kansagara, D., Manaker, S., McLean, R. M., Vijan, S., & Wilt, T. J. (2017). Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline update from the American college of physicians. *Annals of Internal Medicine*, 166(4), 279–290. <https://doi.org/10.7326/M16-1860>
- Rai, M., & Goyal, R. (2018). Pharmacoeconomics in Healthcare. *Pharmaceutical Medicine and Translational Clinical Research*, 465–472. <https://doi.org/10.1016/B978-0-12-802103-3.00034-1>
- Rascati, K. L. (2013). Essentials of Pharmacoeconomics, Second Edition. In *Essentials of Pharmacoeconomics, Second Edition*.
- Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. *Diabetologia*, 60(9), 1577. <https://doi.org/10.1007/S00125-017-4342-Z>
- Rhee, S. Y., Kim, H. J., Ko, S. H., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S. O., Lee, B. W., Choi, K. M., & Kim, J. H. (2017). Monotherapy in patients with type 2 diabetes mellitus. *The Korean Journal of Internal Medicine*, 32(6), 959. <https://doi.org/10.3904/KJIM.2017.312>
- Rhee, S. Y., Kim, H. J., Ko, S. H., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S. O., Lee, B. W., Choi, K. M., Kim, J. H., Kim, T. N., Lee, Y. H., Kim, J. H., Hong, E. G., Kim, J., Lee, W. Y., Song, B., Kim, J. Y., Yang, D. H., ... Hyeongjin Kim. (2017). Monotherapy in Patients with Type 2 Diabetes Mellitus. *Diabetes & Metabolism Journal*, 41(5), 349. <https://doi.org/10.4093/DMJ.2017.41.5.349>
- Roden, M., & Shulman, G. I. (2019). The integrative biology of type 2 diabetes. *Nature*, 576(7785), 51–60. <https://doi.org/10.1038/S41586-019-1797-8>
- RSUD Sumedang. (2022). <https://rsud.sumedangkab.go.id/>
- Sacristán, J. A., Abellán-Perpiñán, J. M., Dilla, T., Soto, J., & Oliva, J. (2020). Some reflections on the use of inappropriate comparators in CEA. *Cost*

Effectiveness and Resource Allocation: C/E, 18(1).
<https://doi.org/10.1186/S12962-020-00226-8>

- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 th edition. *Diabetes Research and Clinical Practice*, 157. <https://doi.org/10.1016/J.DIABRES.2019.107843>
- Sahay, R. K., Mittal, V., Gopal, G. R., Kota, S., Goyal, G., Abhyankar, M., & Revenkar, S. (2020). Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence. *Cureus*, 12(9). <https://doi.org/10.7759/CUREUS.10700>
- Samsudin, Y. B., Mccarthy, J. F., Napitupulu, L., Dewi, R., Hadihardjono, D. N., Rouw, A., Melati, K., Bellotti, W., Tanoto, R., Campbell, S. J., Ariesta, D. L., Setiawan, M. H., Khomsan, A., & Ickowitz, A. (2021). *Mulia Nurhasan Linking food, nutrition and the environment in Indonesia A perspective on sustainable food systems 2 Linking food, nutrition and the environment in Indonesia A perspective on sustainable food systems*. <https://doi.org/10.17528/cifor/008070>
- Sanchez-Rangel, E., & Inzucchi, S. E. (2017). Metformin: clinical use in type 2 diabetes. *Diabetologia*, 60(9), 1586–1593. <https://doi.org/10.1007/S00125-017-4336-X/FIGURES/3>
- Schnell, O., Crocker, J. B., & Weng, J. (2017). Impact of HbA1c Testing at Point of Care on Diabetes Management. *Journal of Diabetes Science and Technology*, 11(3), 611. <https://doi.org/10.1177/1932296816678263>
- Sikaris, K. (2009). Laboratory Advances in Hemoglobin A1c Measurement: The Correlation of Hemoglobin A1c to Blood Glucose. *Journal of Diabetes Science and Technology (Online)*, 3(3), 429. <https://doi.org/10.1177/193229680900300305>
- Simes, B. C., & mac Gregor, G. G. (2019). Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 12, 2125. <https://doi.org/10.2147/DMSO.S212003>
- Singh, S. K. (2018). Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force.” *Indian Journal of Endocrinology and Metabolism*, 22(1), 158. https://doi.org/10.4103/IJEM.IJEM_22_18

- Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P. H., Handelsman, Y., Insel, R. A., Mathieu, C., McElvaine, A. T., Palmer, J. P., Pugliese, A., Schatz, D. A., Sosenko, J. M., Wilding, J. P. H., & Ratner, R. E. (2017). Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. *Diabetes*, *66*(2), 241–255. <https://doi.org/10.2337/DB16-0806>
- Solichah, A. L. (2007). *Analisis Efektivitas Biaya Sulfonilurea-Biguanid dibandingkan Sulfonilurea-Alpha Glucosidase Inhibitor pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan di RSUP Dr. Sardjito Yogyakarta Tahun 2006*.
- Sukmawan, Y. P. (2019). Metformin/Glimepiride and Metformin/Glibenclamide, Which is Better?: A Systematic Review and Meta-Analysis. *Indonesian Journal of Medicine*, *4*(3), 211–218. <https://doi.org/10.26911/THEIJMED.2019.04.03.03>
- Sung, J. Y., Chen, C. I., Hsieh, Y. C., Chen, Y. R., Wu, H. C., Chan, L., Hu, C. J., Hu, H. H., Chiou, H. Y., & Chi, N. F. (2017). Comparison of admission random glucose, fasting glucose, and glycated hemoglobin in predicting the neurological outcome of acute ischemic stroke: a retrospective study. *PeerJ*, *5*(2). <https://doi.org/10.7717/PEERJ.2948>
- Tandon, T., Dubey, A. K., Srivastava, S., Manocha, S., Arora, E., & Hasan, N. (2019). A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. *Journal of Family Medicine and Primary Care*, *8*(3), 955. https://doi.org/10.4103/JFMPC.JFMPC_22_19
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. *Pharmacy Practice*, *19*(1), 1–10. <https://doi.org/10.18549/PHARMRACT.2021.1.2302>
- Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J. F., Montagner, A., & Gourdy, P. (2020). Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*, *63*(3), 453–461. <https://doi.org/10.1007/S00125-019-05040-3/FIGURES/2>
- Tyagi, A., & Pugazhenth, S. (2021). Targeting Insulin Resistance to Treat Cognitive Dysfunction. *Molecular Neurobiology*, *58*(6), 2672. <https://doi.org/10.1007/S12035-021-02283-3>
- Viana, A. L. M., Doriguetto, A. C., Viana, O. M. M. S., Ruela, A. L. M., Freitas, J. T. J., Souto, B. E. M., de Araújo, M. B., & de Araújo Paula, F. B. (2018). Pharmacokinetics and pharmacodynamics of glimepiride

- polymorphs. *International Journal of Pharmaceutics*, 553(1–2), 272–280. <https://doi.org/10.1016/J.IJPHARM.2018.10.050>
- Vries, L. M., Baal, P. H. M., & Brouwer, W. B. F. (2019). Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. *Pharmacoeconomics*, 37(2), 119. <https://doi.org/10.1007/S40273-018-0749-8>
- Wadhwa, R. R., & Marappa-Ganeshan, R. (2022). T Test. *Experimental Design and Analysis*, 10–12. <https://doi.org/10.4135/9781412984218.n3>
- Wafa, W., Septini, R., & Sauriasari, R. (2021). Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study. *Current Diabetes Reviews*, 18(7). <https://doi.org/10.2174/1573399818666211103161917>
- Wei, H., Lan, F., He, Q., Li, H., Zhang, F., Qin, X., & Li, S. (2017). A Comparison Study Between Point-of-Care Testing Systems and Central Laboratory for Determining Blood Glucose in Venous Blood. *Journal of Clinical Laboratory Analysis*, 31(3). <https://doi.org/10.1002/JCLA.22051>
- WHO Library. (2016). Global Report on Diabetes. *Isbn*, 978, 6–86. <http://www.who.int/about/licensing/>
- Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018). Hypertension with diabetes mellitus complications. *Hypertension Research: Official Journal of the Japanese Society of Hypertension*, 41(3), 147–156. <https://doi.org/10.1038/S41440-017-0008-Y>
- Yang, H. K., Lee, S. H., Shin, J., Choi, Y. H., Ahn, Y. B., Lee, B. W., Rhee, E. J., Min, K. W., & Yoon, K. H. (2019). Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *Diabetes & Metabolism Journal*, 43(3), 287–301. <https://doi.org/10.4093/DMJ.2018.0054>
- Yen, F. S., Wei, J. C. C., Lin, M. C., Hsu, C. C., & Hwu, C. M. (2021). Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes. *BMC Endocrine Disorders*, 21(1). <https://doi.org/10.1186/S12902-021-00690-0>
- Yuswantina, R., & Dyahariesti, N. (2017). ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ANTIDIABETES ORAL TUNGGAL DAN KOMBINASI PADA PASIEN BPJS PENDERITA DIABETES MILLITUS TIPE 2 DI RUMAH SAKIT X. *Pemanfaatan Minyak Sereh Menjadi Berbagai-Macam Produk*, 12(1), 1137–1143.

- Zake, D. M., Kurlovics, J., Zaharenko, L., Komasilovs, V., Klovins, J., & Stalidzans, E. (2021). Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues. *PLoS ONE*, *16*(4). <https://doi.org/10.1371/JOURNAL.PONE.0249594>
- Zerga, A. A., & Bezabih, A. M. (2020). Metabolic syndrome and lifestyle factors among type 2 diabetes mellitus patients in Dessie Referral Hospital, Amhara region, Ethiopia. *PLoS ONE*, *15*(11). <https://doi.org/10.1371/JOURNAL.PONE.0241432>
- Zhang, F., Xu, S., Tang, L., Pan, X., & Tong, N. (2020). Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: A systematic review and network meta-analysis of randomized controlled trials. *Frontiers in Endocrinology*, *11*, 288. <https://doi.org/10.3389/FENDO.2020.00288/BIBTEX>
- Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., & Meeran, K. (2018). Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. *JAMA*, *319*(15), 1580. <https://doi.org/10.1001/JAMA.2018.3024>
- Zozaya, N., Capel, M., Simón, S., & Soto-González, A. (2019). A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. <https://doi.org/10.1177/2284240319876574>, 2019, 228424031987657. <https://doi.org/10.1177/2284240319876574>